Autism

SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept.…

2 years ago

Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of…

2 years ago

PaxMedica, Inc. Announces Pricing of Initial Public Offering

Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD” TARRYTOWN, NY, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via…

2 years ago

Scisparc Announces the Full Exercise of Pre-Funded Warrants

The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug.…

2 years ago

SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel,…

2 years ago

SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD…

2 years ago

Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for…

2 years ago

ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

Oryzon invests $8.1 million in R&D in the first half 2022MADRID, Spain and BOSTON, July 22, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid…

2 years ago